HRP20200882T1 - Vezujuće molekule specifične za asct2 i njihova uporaba - Google Patents

Vezujuće molekule specifične za asct2 i njihova uporaba Download PDF

Info

Publication number
HRP20200882T1
HRP20200882T1 HRP20200882TT HRP20200882T HRP20200882T1 HR P20200882 T1 HRP20200882 T1 HR P20200882T1 HR P20200882T T HRP20200882T T HR P20200882TT HR P20200882 T HRP20200882 T HR P20200882T HR P20200882 T1 HRP20200882 T1 HR P20200882T1
Authority
HR
Croatia
Prior art keywords
antibody
seq
amino acid
acid sequence
antigen
Prior art date
Application number
HRP20200882TT
Other languages
English (en)
Inventor
Nabendu PORE
Martin J. BORROK III
Partha Chowdhury
Emil F. Michelotti
David A. Tice
Robert E. Hollingsworth
Chien-Ying CHANG
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Publication of HRP20200882T1 publication Critical patent/HRP20200882T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (20)

1. Protutijelo ili njegov ulomak koji veže antigen, koji se specifično veže na epitop ASCT2, pri čemu protutijelo ili ulomak koji veže antigen sadrži tri regije koja određuju komplementarnost teškog lanca (HCDR) varijabilne regije teškog lanca (VH) i tri regije koja određuju komplementarnost lakog lanca (LCDR) varijabilne regije lakog lanca (VL), naznačeno time što protutijelo ili njegov ulomak koji veže antigen sadrži: (a) HCDR1 sekvence aminokiseline iz SEQ ID NO: 10; HCDR2 sekvence aminokiseline iz SEQ ID NO: 11; HCDR3 sekvence aminokiseline iz SEQ ID NO: 12; LCDR1 sekvence aminokiseline iz SEQ ID NO: 13; LCDR2 sekvence aminokiseline iz SEQ ID NO: 14; i LCDR3 sekvence aminokiseline iz SEQ ID NO: 15; ili (b) HCDR1 sekvence aminokiseline iz SEQ ID NO: 16; HCDR2 sekvence aminokiseline iz SEQ ID NO: 17; HCDR3 sekvence aminokiseline iz SEQ ID NO: 18; LCDR1 sekvence aminokiseline iz SEQ ID NO: 19; LCDR2 sekvence aminokiseline iz SEQ ID NO: 20; i LCDR3 sekvence aminokiseline iz SEQ ID NO: 21.
2. Protutijelo ili ulomak koji veže antigen prema patentnom zahtjevu 1, naznačeno time što: (a) VH sadrži sekvencu aminokiseline SEQ ID NO: 1 i pri čemu VL sadrži sekvencu aminokiseline SEQ ID NO: 2; (b) VH sadrži sekvencu aminokiseline SEQ ID NO: 3, i pri čemu VL sadrži sekvencu aminokiseline SEQ ID NO: 4; (c) VH sadrži sekvencu aminokiseline SEQ ID NO: 5, i pri čemu VL sadrži sekvencu aminokiseline SEQ ID NO: 6; ili (d) VH sadrži sekvencu aminokiseline SEQ ID NO: 7, i pri čemu VL sadrži sekvencu aminokiseline SEQ ID NO: 8.
3. Protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačeno time što VH sadrži sekvencu aminokiseline iz SEQ ID NO: 5 i VL sadrži sekvencu aminokiseline iz SEQ ID NO: 6.
4. Protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačeno time što VH sadrži sekvencu aminokiseline SEQ ID NO: 7 i VL sadrži sekvencu aminokiseline SEQ ID NO: 8.
5. Protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time što protutijelo ili ulomak koji veže antigen sadrži IgG konstantnu regiju koja sadrži umetanje cisteina (C) između serina (S na položaju 239 i valina (V) na položaju 240, pri čemu označavanje odgovara EU indeksu u Kabatu.
6. Protutijelo ili ulomak koji veže antigen prema patentnom zahtjevu 5, naznačeno time što protutijelo sadrži teški lanac sekvence aminokiseline iz SEQ ID NO: 9.
7. Protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 6, naznačeno time što nakon vezanja protutijela na ASCT2 na staničnoj površini, protutijelo internalizira u stanicu.
8. Protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 7, naznačeno time što sadrži konstantnu regiju lakog lanca odabranu iz skupine koja se sastoji od ljudske konstantne regije kapa i ljudske konstantne regije lambda.
9. Protutijelo ili ulomak koji veže antigen prema patentnom zahtjevu 8, naznačeno time što protutijelo sadrži ljudsku kapa konstantnu regiju iz SEQ ID NO: 26.
10. Protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 9, naznačeno time što je nadalje konjugirano na citotoksin odabran iz skupine koja sadrži antimikrobno sredstvo, terapijsko sredstvo, predlijek, peptid, protein, enzim, lipid, modifikator biološkog odgovora, farmaceutsko sredstvo, limfokin, heterologno protutijelo, ulomak heterolognog protutijela, oznaku koja se može detektirati, polietilen glikol (PEG), radioizotop, i kombinaciju dva ili više bilo kojih navedenih citotoksina.
11. Protutijelo ili ulomak koji veže antigen prema patentnom zahtjevu 10, naznačeno time što je konjugirano sa citotoksinom.
12. Protutijelo ili ulomak koji veže antigen prema patentnom zahtjevu 11, naznačeno time što je citotoksin odabran od derivata tubulizina i pirolobenzodiazepina.
13. Protutijelo ili ulomak koji veže antigen prema patentnom zahtjevu 12, naznačeno time što je derivat tubulizina tubulizin AZ1508.
14. Protutijelo ili ulomak koji veže antigen prema patentnom zahtjevu 12, naznačeno time što je pirolobenzodiazepin odabran od SG3315 i SG3249.
15. Protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 14, naznačeno time što se protutijelo veže na ljudski ASCT2 i ASCT2 makaki majmuna.
16. Protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 15, naznačeno time što se protutijelo ne veže specifično za ljudski ASCT1.
17. Farmaceutski pripravak naznačen time što sadrži protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 16 i farmaceutski prihvatljiv nosač.
18. Polinukleotid ili kombinacija polinukleotida koji kodiraju protutijelo ili njegov ulomak koji veže antigen u skladu s bilo kojim od zahtjeva 1 do 16.
19. Postupak za izradu protutijela ili njegovog ulomka koji veže antigen prema bilo kojem od zahtjeva 1 do 16 naznačen time što obuhvaća uzgoj domaćina koji sadrži polinukleotid prema zahtjevu 18.
20. Protutijelo ili ulomak koji veže za antigen prema bilo kojem od zahtjeva 1 do 16 ili farmaceutski pripravak prema zahtjevu 17, naznačen time što se upotrebljava u liječenju raka koji karakterizira prekomjerna ekspresija ASCT2, pri čemu navedenu liječenje obuhvaća primjenu subjektu kojem je potrebno učinkovite količine navedenog protutijela ili ulomka koji veže antigen ili navedenog farmaceutskog pripravka.
HRP20200882TT 2015-11-10 2020-06-02 Vezujuće molekule specifične za asct2 i njihova uporaba HRP20200882T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562253371P 2015-11-10 2015-11-10
US201562253774P 2015-11-11 2015-11-11
EP16802197.0A EP3374398B1 (en) 2015-11-10 2016-11-10 Binding molecules specific for asct2 and uses thereof
PCT/US2016/061219 WO2017083451A1 (en) 2015-11-10 2016-11-10 Binding molecules specific for asct2 and uses thereof

Publications (1)

Publication Number Publication Date
HRP20200882T1 true HRP20200882T1 (hr) 2020-09-04

Family

ID=57421946

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200882TT HRP20200882T1 (hr) 2015-11-10 2020-06-02 Vezujuće molekule specifične za asct2 i njihova uporaba

Country Status (29)

Country Link
US (2) US10829554B2 (hr)
EP (2) EP3374398B1 (hr)
JP (1) JP6898925B2 (hr)
KR (1) KR20180073675A (hr)
CN (1) CN108290949B (hr)
AU (1) AU2016352967A1 (hr)
BR (1) BR112018008983A2 (hr)
CA (1) CA3003468C (hr)
CL (1) CL2018001238A1 (hr)
CO (1) CO2018004930A2 (hr)
CY (1) CY1123525T1 (hr)
DK (1) DK3374398T3 (hr)
ES (2) ES2796560T3 (hr)
HK (1) HK1258317A1 (hr)
HR (1) HRP20200882T1 (hr)
HU (1) HUE050312T2 (hr)
IL (1) IL259036B (hr)
LT (1) LT3374398T (hr)
MX (1) MX2018005541A (hr)
MY (1) MY192146A (hr)
PL (1) PL3374398T3 (hr)
PT (1) PT3374398T (hr)
RS (1) RS60389B1 (hr)
RU (1) RU2710194C9 (hr)
SG (2) SG11201803068YA (hr)
SI (1) SI3374398T1 (hr)
TW (1) TWI726936B (hr)
WO (1) WO2017083451A1 (hr)
ZA (1) ZA201803841B (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020503258A (ja) * 2016-11-10 2020-01-30 メディミューン，エルエルシー Ａｓｃｔ２特異的結合分子及びその使用
WO2020056021A1 (en) * 2018-09-11 2020-03-19 The Johns Hopkins University Force - dependent drug release system to enhance selective killing and minimize adverse effects in cancer treatment
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
EP4382120A1 (en) * 2022-12-05 2024-06-12 Institut Regional du Cancer de Montpellier Anti-slc1a4 monoclonal antibodies and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58180487A (ja) 1982-04-16 1983-10-21 Kyowa Hakko Kogyo Co Ltd 抗生物質ｄｃ−８１およびその製造法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP1186660A3 (fr) 1985-03-30 2002-03-20 KAUFFMAN, Stuart A. Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ES2353268T3 (es) 1999-07-02 2011-02-28 Morphosys Ag Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est.
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US7816377B2 (en) 2002-07-09 2010-10-19 R&D-Biopharmaceuticals Gmbh Tubulysin analogues
AU2003253048A1 (en) 2002-07-09 2004-01-23 Morphochem Aktiengellschaft Fur Kombinatorische Chemie Tubulysin conjugates
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EA010570B1 (ru) 2002-11-07 2008-10-30 Иммьюноджен, Инк. Антитело к cd33 и способы его применения
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
KR20070072510A (ko) 2004-08-30 2007-07-04 론자 바이올로직스 피엘씨 항체 정제를 위한 친화도- 및 이온 교환- 크로마토그래피
US20090123388A1 (en) * 2005-01-14 2009-05-14 Medical College Of Georgia Research Institute Prodrugs of Short-Chain Fatty Acids and Treatment Methods
EP2389946A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
FR2912314B1 (fr) * 2007-02-09 2012-08-03 Geneuro Sa Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.
WO2009012958A2 (en) 2007-07-20 2009-01-29 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
US8476451B2 (en) 2007-07-20 2013-07-02 The Regents Of The University Of California Tubulysin D analogues
EP2209374B1 (en) 2007-10-25 2014-12-03 Endocyte, Inc. Tubulysins and processes for preparing
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US8168586B1 (en) 2007-11-21 2012-05-01 Celera Corporation Cancer targets and uses thereof
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
JP5730570B2 (ja) * 2008-07-17 2015-06-10 協和発酵キリン株式会社 抗システムａｓｃアミノ酸トランスポーター２（ａｓｃｔ２）抗体
WO2010031185A1 (en) 2008-09-19 2010-03-25 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
WO2011087091A1 (ja) * 2010-01-15 2011-07-21 協和発酵キリン株式会社 抗システムａｓｃアミノ酸トランスポーター２（ａｓｃｔ２）抗体
CN103140227B (zh) 2010-08-06 2016-01-20 恩多塞特公司 制备微管蛋白细胞溶素的方法
WO2013176626A1 (en) * 2012-05-25 2013-11-28 National University Of Singapore Method of identifying foetal erythroblast
PT2839860T (pt) 2012-10-12 2019-07-29 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015155345A1 (en) 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
WO2015157592A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
PT3129406T (pt) * 2014-04-11 2019-04-24 Medimmune Llc Compostos conjugados que compreendem anticorpos com manipulação de cisteínas
MX2016013373A (es) 2014-04-11 2017-05-02 Medimmune Llc Derivados de tubulisina.
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
JP2020503258A (ja) 2016-11-10 2020-01-30 メディミューン，エルエルシー Ａｓｃｔ２特異的結合分子及びその使用

Also Published As

Publication number Publication date
SI3374398T1 (sl) 2020-07-31
PT3374398T (pt) 2020-06-16
SG11201803068YA (en) 2018-05-30
PL3374398T3 (pl) 2020-08-24
RU2710194C2 (ru) 2019-12-24
US10829554B2 (en) 2020-11-10
IL259036A (en) 2018-06-28
ES2959663T3 (es) 2024-02-27
RU2018120695A3 (hr) 2019-12-16
WO2017083451A8 (en) 2018-02-01
HUE050312T2 (hu) 2020-11-30
LT3374398T (lt) 2020-09-10
SG10202103712VA (en) 2021-05-28
CL2018001238A1 (es) 2018-10-12
US20180273617A1 (en) 2018-09-27
JP2018535674A (ja) 2018-12-06
NZ743023A (en) 2021-08-27
EP3374398B1 (en) 2020-03-18
IL259036B (en) 2020-04-30
CA3003468A1 (en) 2017-05-18
TW201726738A (zh) 2017-08-01
BR112018008983A2 (pt) 2018-10-30
CA3003468C (en) 2024-06-18
RS60389B1 (sr) 2020-07-31
JP6898925B2 (ja) 2021-07-07
MY192146A (en) 2022-08-01
RU2018120695A (ru) 2019-12-16
RU2710194C9 (ru) 2020-09-14
EP3374398A1 (en) 2018-09-19
TWI726936B (zh) 2021-05-11
MX2018005541A (es) 2018-08-01
KR20180073675A (ko) 2018-07-02
US11608375B2 (en) 2023-03-21
AU2016352967A1 (en) 2018-06-21
ZA201803841B (en) 2019-04-24
DK3374398T3 (da) 2020-06-08
CY1123525T1 (el) 2022-03-24
WO2017083451A1 (en) 2017-05-18
EP3719039A1 (en) 2020-10-07
CN108290949A (zh) 2018-07-17
ES2796560T3 (es) 2020-11-27
HK1258317A1 (zh) 2019-11-08
US20210024629A1 (en) 2021-01-28
EP3719039B1 (en) 2023-07-26
CN108290949B (zh) 2021-12-14
CO2018004930A2 (es) 2018-11-30

Similar Documents

Publication Publication Date Title
HRP20200882T1 (hr) Vezujuće molekule specifične za asct2 i njihova uporaba
HRP20211125T1 (hr) Konjugati protutijelo-lijek koji se temelje na eribulinu i postupci uporabe
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
HRP20151019T1 (hr) PROTUTIJELA PROTIV c-MET
HRP20160485T1 (hr) Anti-mezotelinska protutijela i njihova uporaba
JP2013121353A5 (hr)
HRP20191335T1 (hr) Anti-egfrviii antitijela i njihove primjene
HRP20190486T1 (hr) Konjugirani spojevi koji sadrže cisteinska protutijela dobivena inženjeringom
HRP20231578T1 (hr) Molekule protutijela na april i njihove uporabe
HRP20191678T1 (hr) Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena
RU2486198C2 (ru) Антиген, ассоциированный с ревматоидным артритом
IL299072A (en) Antibodies and methods for using them
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
CO6230999A2 (es) Anticuerpo anti-esclerostina
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
HRP20212028T1 (hr) Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3
NZ628943A (en) Human antibodies to clostridium difficile toxins
JP2018536393A5 (hr)
NZ598391A (en) Anti-hepcidin antibodies and uses thereof
HRP20201432T1 (hr) Il-17a sredstvo za vezivanje i njegove uporabe
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
HRP20171775T1 (hr) Molekule protutijela koje vežu trombin i njihova uporaba
JP2017510559A5 (hr)
PE20141151A1 (es) Proteinas de union al antigeno cd27l